Department of Dermatology, University of Erlangen, Nuremburg, Germany.
Head Neck. 2012 Dec;34(12):1734-46. doi: 10.1002/hed.22004. Epub 2012 Jan 27.
We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a "penetrin" peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled.
Enrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections.
Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced.
This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN.
我们在晚期头颈部鳞状细胞癌（SCCHN）患者中使用特洛伊疫苗进行了一项试点研究。这些疫苗由 HLA-I 和 HLA-II 限制的黑色素瘤抗原 E（MAGE）-A3 或人乳头瘤病毒（HPV）-16 衍生肽组成，通过弗林切割接头连接，并与源自 HIV-TAT 的“穿透素”肽序列连接。对 31 名 SCCHN 患者进行了试验筛选，有 5 名患者入选。
入选患者每 4 周接受 300μg 特洛伊肽加 Montanide 和粒细胞-巨噬细胞集落刺激因子（GM-CSF）治疗，最多 4 次注射。
接种疫苗后，5 名患者中的 4 名患者的外周血单核细胞（PBMC）能够识别完整的特洛伊结构和组成的 HLA-II 肽，而对 HLA-I 限制的肽的反应则不那么明显。
这种治疗方案似乎具有可接受的毒性，并在一组晚期 SCCHN 患者中引发针对 HLA-II 限制表位的可测量的全身免疫反应。
